Lipocine (LPCN) EBIT (QoQ) (2013 - 2025)
Lipocine (LPCN) EBIT (QoQ) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -39.79% |
| Jun 30, 2025 | -15.03% |
| Mar 31, 2025 | -235.25% |
| Dec 31, 2024 | 158.75% |
| Sep 30, 2024 | 20.11% |
| Jun 30, 2024 | -202.17% |
| Mar 31, 2024 | 224.26% |
| Dec 31, 2023 | 63.18% |
| Sep 30, 2023 | -78.06% |
| Jun 30, 2023 | 8.83% |
| Mar 31, 2023 | -69.42% |
| Dec 31, 2022 | 11.68% |
| Sep 30, 2022 | 17.81% |
| Jun 30, 2022 | -12.64% |
| Mar 31, 2022 | -124.50% |
| Dec 31, 2021 | 461.78% |
| Sep 30, 2021 | -18.17% |
| Jun 30, 2021 | 3.99% |
| Mar 31, 2021 | 35.14% |
| Dec 31, 2020 | -9.75% |